Amgen Announces Appointment Of Fred Hassan To Board Of Directors

Article

Amgen today announced the appointment of Fred Hassan, partner and managing director of Warburg Pincus LLC, to the Amgen Board of Directors.

PRESS RELEASE

THOUSAND OAKS, Calif.

,

July 30, 2015

/PRNewswire/ --

Amgen

(NASDAQ: AMGN) today announced the appointment of

Fred Hassan

, partner and managing director of

Warburg Pincus LLC

, to the Amgen Board of Directors.

"We are pleased to welcome

Fred Hassan

and the deep, global experience he brings in the biopharmaceuticals sector to the Amgen Board," said

Robert A. Bradway

, chairman and chief executive officer of Amgen. "Fred's breadth of operational expertise and commitment to innovation will serve

Amgen

well."

Mr. Hassan has been Partner and Managing Director at

Warburg Pincus LLC

, a global private equity investment institution, since 2011 and, prior to that, served as Senior Advisor from 2009 to 2010. Mr. Hassan was Chairman of the Board and Chief Executive Officer of

Schering-Plough Corporation

from 2003 to 2009. Prior to this, Mr. Hassan was Chairman, President and Chief Executive Officer of

Pharmacia Corporation

, from 2001 to 2003. Before assuming these roles, he had served as President and Chief Executive Officer of

Pharmacia Corporation

from its creation in 2000 as a result of the merger of

Pharmacia & Upjohn, Inc.

with

Monsanto Company

. He was President and Chief Executive Officer of

Pharmacia & Upjohn, Inc.

beginning in 1997. Mr. Hassan previously held senior positions with Wyeth (formerly known as American Home Products), including that of Executive Vice President with responsibility for its pharmaceutical and medical products businesses, and served as a member of the board from 1995 to 1997. Prior to that, Mr. Hassan held various roles at

Sandoz Pharmaceuticals

and headed its U.S. pharmaceuticals businesses.

Mr. Hassan has been a director of

Time Warner Inc.

, a media company, since 2009. Mr. Hassan was a director of

Avon Products, Inc.

, a manufacturer and marketer of beauty and related products, from 1999 until 2013 and served as lead independent director from 2009 to 2012 and Chairman of the Board between January and April 2013. Mr. Hassan was Chairman of the Board of Bausch & Lomb, from 2010 until its acquisition by

Valeant Pharmaceuticals International, Inc.

, a pharmaceutical company, in 2013. Mr. Hassan served on the board of directors of

Valeant Pharmaceuticals International, Inc.

between

August 2013

and

May 2014

.

Mr. Hassan's book, "Reinvent - A Leader's Playbook for Serial Success," was published in 2013 by Wiley and describes the linkage between attitude, culture, execution and driven performance. In 2014, a CNBC panel named Mr. Hassan to a list of those who have had the most profound impact on the world of business in the previous quarter century.

Mr. Hassan will serve on the Audit Committee and the Compensation and Management Development Committee of the Board.

Related Videos
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit:  JPC-PROD | stock.adobe.com - Choosing method of contraception : Birth control pills, an injection syringe, condom, IUD-method, on grey
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.